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ABSTRACT
Thymidylate synthase (TS) is a tumor-associated enzyme critical for DNA replication and main 50-
fluorouracil (50-FU) target. TSPP/VAC1 is a multi-arm trial phase-Ib trial program aimed to investigate the
toxicity and biomodulatory activity of a poly-epitope-peptide vaccine to TS (TSPP) in cancer patients (pts).
Here, we present the results of the TSPP/VAC1/arm C trial aimed to evaluate TSPP in combination with
chemo-immunotherapy in pretreated metastatic colo-rectal cancer (mCRC) pts. Twenty-nine pts, 14 males
and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000 mg/sqm, day-1], oxaliplatin
[OX; 80 mg/sqm, day-2], levofolinate [100 mg/sqm, days 1–2], bolus/infusional 50-FU [400 mg/800 mg/
sqm, days 1–2], sargramostim [50 mg, days 3–7/q30], and interleukin-2 [sc. 0.5 MIU twice a day, days 8–14/
18–30] [GOLFIG-regimen]. Seventeen pts received sc. TSPP injections at escalating dosage [3 pts, 100 mg
(DL-1); 3 pts, 200 mg (DL-2) and 11pts, 300 mg (DL-3)] one week after each chemotherapy cycle
(concomitant module), while 10 out 12 pts received TSPP (300 mg) after 12 GOLFIG courses [dose level
(DL)-0] (sequential module). TSPP MTD was not achieved. Adverse events consisted in swelling/erythema
at injection sites (17 cases), G1–2 haematological (16 cases) and gastro-enteric events (12), fever, rhinitis,
conjunctivitis, and poly-arthralgia and rise in auto-antibodies [ANA, ENA, c-ANCA, p-ANCA in the DL1–3
pts]. Both treatment-modules showed immunomodulating and antitumor activity (disease-control-rate,
DL1–3 and DL0 were 70.6% and 83.3%, respectively) with a better survival recorded in the second group
[median OS DL1–3 vs. DL0 D 8 vs. 16 mo, p D 0.049]. The promising long-term survival produced by the
sequential treatment module deserves further phase II evaluation.
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Introduction
Active specific immunotherapy (ASI) is a re-emerging antican-
cer treatment strategy and immune-checkpoint regulator
monoclonal antibodies (mAbs) and tumor-associate-antigen
(TAA)-specific vaccine formulations are currently under active
investigation in cancer pts.1-5 In the last 15 years, several
attempts have been made to combine different therapeutic
modalities with ASI in the treatment of solid malignancies in
order to improve its antitumor efficacy. Radio- and chemo-
immunotherapy have produced promising results in both pre-
clinical and clinical studies.6-11
We generated and characterized new vaccine constructs
able to direct an effective immune-response to molecular
structures which are over-expressed in cancer cells and, at the
same time, are critical for their growth, survival, and diffusion,
as the Epidermal growth Factor Receptor [EGFR], the para-
thyroid hormone related peptide [PTHrP] and TS.6-9 TS, in
particular, is a cancer-associated target enzyme, inhibited by
several anticancer drugs (antimetabolites) such as 50-FU, a
cytotoxic drug which is a basic component of different regi-
mens for the treatment of mCRC and other common malig-
nancies.10-12 50-FU is a pro-drug, that upon transformation to
50-FdUMP, binds and permanently inhibits the catalytic site
of TS in the presence of levo-folinate. TS is responsible for
deoxy-uridine monophosphate (dUMP) methylation to thymi-
dylate, a crucial component for DNA synthesis and repair,
whose expression is S phase specific, and is often over-
expressed in tumor tissue. TS is an mRNA binding protein
which auto-regulates its expression depending on the intracel-
lular levels of metabolites, cofactors, and substrates. Therefore,
cancer cell exposure to 50-FU, by inducing thymidylate deple-
tion, promotes transient TS over-expression within 24/48 h in
the surviving cells. TS-overexpression in tumor tissue, is
finally predictive of 50-FU resistance and poor prognosis in
mCRC pts.10-12 We previously demonstrated that TS is a
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potential candidate target for ASI, and identified 3 TS-derived
epitopes with HLA-A()02.01 amino-acid anchorage motifs
(TS-1, TS-2, and TS-3), recognized by human cytotoxic- T-
lymphocytes (CTLs).8 We also characterized a 27-mer peptide,
designated as TSPP, which combines the amino-acidic sequen-
ces of these peptides.9 We showed that TSPP elicits a powerful
multi-epitope specific CTL response with antitumor activity in
vitro.9,13 and was safe and immunogenic in HHD mice (trans-
genic for the expression of HLA-A()02.01 and human
CD8a). In this murine model, TSPP vaccination prevented
and/or eradicated tumors after injection of syngeneic EL4/
HHD lymphoma cells.9,13 As an additional finding, TSPP anti-
tumor activity, was greatly enhanced when used in combina-
tion with 50-FU-based chemotherapy.9,13 Indeed, we observed
the better results when TSPP immunizations were weekly
administered in alternate combination with the GOLF poly-
chemotherapy,13 a previously characterized multi-drug regi-
men with GEM, OX, levofolinic acid (LF) and infusional 50-
FU.14,15 50-FdUMP binds TS and promotes its ubiquitination
and proteolysis by the proteasome system.12 TS processing by
the proteasomes, in turn, promotes the assembling of class-I
HLA/TS-epitope peptides which are subsequently transported
to the membrane becoming available for recognition by spe-
cific CTL precursors.9,13 Additionally, thymidine depletion in
cancer cells also promotes TS over-expression, thus augment-
ing the amounts of TS epitopes available for CTL recognition.
We already demonstrated that tumor cell exposure to GOLF
regimen increases the expression of multiple TAA (like TS,
CEA, and EGFR), enhances the expression of danger signals
and “eat-me” molecules, and induces immunogenicity in colon
and breast cancer cell models in vitro.9,13,14,16-19 These preclin-
ical findings provided a clear rationale to investigate the
GOLF regimen in combination with an immune-adjuvant IG-
1 cytokine regimen (sc. Interleukin (IL)-2 and sc. Granulo-
cyte-Macrophage colony-stimulating-factor(GM-CSF) (GOL-
FIG chemo-immunotherapy regimen) in colon cancer pts and
successively, in combination with TSPP-based immunother-
apy. The GOLFIG regimen has been already evaluated in
mCRC pts, resulting safe, with significant immune-modulating
effects and powerful antitumor activity.15,20,21 On these bases,
we designed a multi-arm phase Ib trial program (TSPP/VAC-
1) to investigate the toxicity and immune-biological activity of
TSPP vaccination in cancer pts. Each arm of the program was
defined on a dose-finding setting, and aimed to test TSPP vac-
cination alone (Arm A) or associated with GM-CSF and IL-2
(Arm B) or in combination with the GOLFIG regimen (Arm
C). The results obtained in the first two arm trials suggested
that TSPP is safe, produces self-limiting auto-immunity signs,
is able to generate a TS-specific CTL response with significant
rise in serum auto-antibodies (AAbs) such as anti-nuclear Abs
(ANA); extractable nuclear antigen Abs (ENA); anti-protein-
ase-3 anti-neutrophil cytoplasmic Abs (P-ANCA), and anti-
myeloperoxidase anti-neutrophil cytoplasmic Abs (C-
ANCA)].22
In the present study, we report the results concerning the
arm C trial of the TSPP/VAC-1 program. This part of the study
was planned to enroll pretreated mCRC pts, who received
TSPP vaccination concomitantly (alternate weeks) or
sequentially (after 12 GOLFIG courses) to the GOLFIG chemo-
immunotherapy.
Patient and methods
The TSPP/VAC-1 is a multi-arm phase Ib trial program
designed to test the toxicity and immunological activity of
TSPP, a new poly-epitope cancer vaccine to TS, in different
therapeutic conditions and in advanced cancer pts. The proto-
col consisted of three parallel and independent trial arms
designed to test TSPP vaccination alone (Arm A) and in combi-
nation with immune-adjuvant IG-1 regimen (Arm B) and in
combination with GOLFIG chemo-immunotherapy regimen
(Arm C). The latter trial arm was reserved to mCRC pts only
and evaluated the effects of peptide vaccination, administered
concomitantly with the GOLFIG regimens (DL1–3), and/or
sequentially (DL0) after 10/12 courses of this regimen.
Ethical considerations and study design
The study was designed according to good clinical practice
(GCP) recommendations, authorized by the Italian National
Institute of Health (Istituto Superiore di Sanita) and by the Ital-
ian Ministry of Health, approved by the University of Siena
Ethical Committee Board (equivalent to Human Subject Com-
mittee of Investigational Review Board) and registered with the
TSPP/VAC-1 code, Eudract: # 2009–016897–33. This phase Ib
study was planned as a dose escalation trial program, in three
parallel and independent arms (A, B, and C). TSPP dose-escala-
tion was planned according to the Fibonacci’s series. The first
cohort of pts received 100 mg of peptide (DL1), the second,
200 mg (DL2), and the third 300 mg (DL3), every 21 d new pts
could be enrolled in higher dose level cohorts, only if no Grade
IV event were demonstrated in pts treated with lower doses.
Pts assigned to the arm A received treatment with vaccine pep-
tide alone, those of arm B received TSPP and sc. GM-CSF (Sar-
gramostim/Leukine!, Berlex, USA) (50 mg days 1–5) and sc.
IL-2 (Proleukin!, Novartis, Switzerland) (0.5 MIU bi-daily,
days 6–15), while those of arm C/DL1–3 received peptide vacci-
nation 7 d after the beginning of the chemo-immunotherapy
cycle with gemcitabine 1 g/sqm on the day 1, oxaliplatin
85 mg/sqm on the day 2, Levofolinic acid 100 mg/sqm on the
days 1 and 2, bolus 50-FU 400 mg/sqm on days 1 and 2, and
infusional 50-FU 800 mg/sqm on days 1 and 2, every 15 d these
pts also received sc. GM-CSF (50 mg days 3–7) and sc. recombi-
nant (r) IL-2 (Aldesleukine, 0.5 MIU bi-daily on days 8–14 and
17–29). Pts in arm C/DL0 were aimed to receive TSPP vaccina-
tion alike arm B, after they had received 12 GOLFIG
courses.15,23
TSPP vaccine
TSPP (YMIAHITGLFLDSLGFSTTLGDAHIYL) was synthe-
sized and characterized by good manufacturing practice
(GMP) procedures by the American Peptide Ltd (Rockville,
MD, USA). The aseptic vial filling process was performed by
the Pharmacy of the Azienda Ospedaliera Universitaria Senese,
which also performed the stability study, endotoxin evaluation,
and chemical related toxicity analysis of the product. TSPP was
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dissolved in DMSO (1.5 mg peptide in 1 mL DMSO). The exact
peptide dose (100, 200, or 300 mg), was diluted with PBS in a
volume of 250 mL, and then 1:2 diluted with Montanide ISA
720 VG ST (Seppic, Milan, Italy) as adjuvant. The final volume
of the vaccine was 500 mL/dose.
Patients
The study-arm-C trial was planned to evaluate the immunolog-
ical activity and toxicity of TSPP in combination with GOLFIG
chemo-immunotherapy, in mCRC pts, who had received at
least two standard treatment lines. The primary endpoints of
the study were the identification of the maximal tolerated dose
(MTD) and most effective biological dose (MEBD) of TSPP
peptide, by evaluating the frequency of adverse events per dose
level and predefined immune-biological events in three cohorts
of three pts each. Evidence of antitumor activity was a second-
ary endpoint. The inclusion criteria were the following: written
informed consent, histological diagnosis of malignant disease,
at least two previous chemotherapy lines for advanced disease,
measurable disease (according to WHO tumor response crite-
ria), ECOG performance status 2, normal renal and hepatic
functions, white blood cell count 2,500/mm3, hemoglobin lev-
els 9 g/dL, platelet cell count 100,000/mm3, and normal
heart function. The exclusion criteria were the following: any
major organ failure, unstabilized central nervous system
involvement, second malignancies, active infectious disease,
major inflammatory and autoimmune rheumatic diseases, and
acquired immune-suppression. Treatment allocation was not
masked. Standard clinical and laboratory evaluation (clinical
history, physical examination, blood count and chemistry,
serum dosage of C-reactive protein (CRP), erythrocyte-sedi-
mentation rate (ESR), lactate dehydrogenase (LDH), rheuma-
toid factor, carcinoembryonic antigen (CEA) and CA19.9
assays, chest X-rays, and ultrasound abdominal scans, were
performed at baseline and repeated every 6 weeks. Pts’ sera
were tested for ANA by IFA, (starting dilution 1:160) (SSA
HEp2000, ImmunoConcepts), EliASymphony screening
(Thermo Fisher Scientific), and further ELiA tests were per-
formed for single ANA specificities; ANCA; p-ANCA; C-
ANCA ENA were tested on Phadia250 instrument; ANCA
were measured by indirect immunofluorescence using INOVA
substrate. Contrast CT scans were scheduled every three
months. Pts enrolled in the arm C/DL1–3 received combined
TSPP/GOLFIG treatment for a maximal of 12 cycles, then those
who did not progress, received TSPP vaccination every 21 d at
the dosage of 300 mg until disease progression, occurrence of
unacceptable toxicity, clinical judgment, or withdrawal of con-
sent. Any further treatment decision after disease progression
was left to the physician in charge. Adverse events, toxicity, and
treatment response were evaluated according to WHO
classification.
ELISA assays and multiplex analysis
Serum levels of Interferon(IFN)g, Tumor necrosis factor
(TNF)-a, IL10, IL4, IL12, IL10, and IL17 cytokines were mea-
sured using Bio-Plex human cytokine multiplex kits (Bio-Rad
Inc., Hercules, CA). The fluorescence intensity of the beads was
measured by using the Bio-Plex array reader. Bio-Plex Manager
software with five-parametric-curve fitting was used for data
analysis. Serum levels of IL6 and IL8 were measured by using
human cytokine ELISA kits and analyzed according to the
manufacturer’s protocol (Bio-Rad Inc., Hercules, CA).
Fluorescence-activated cell sorting analysis of patient
peripheral blood mononuclear cells (PBMC)
The pts’ PBMCs were purified by Ficoll-Hypaque (Celbio S.P.
A., Italy) gradient separation of buffy coats of heparinized
blood samples and analyzed by Fluorescence-activated cell sort-
ing (FACS) analysis, as described in previous studies.24,25
PBMC were stained with different pools of labeled mAbs
(CD4V450, CD45RAPE, CD62LFITC, CCR7PE-Cy7, PharMin-
gen;CD8CPerCPCy 5.5, CD45ROAPC, CD3FITC, CD19FITC,
CD14FITC, CD11cAPC, CD16PE, Rat IgG2aFITC, Mouse
IgG1, Becton Dickinson, Italy; CD56 APC, Mouse IgG2a APC
Immunotools, DE; CD15 PE ABCam, UK; CD25 PE, FoxP3
FITC, eBioscence, UK) and examined by a FACScalibur BD
instrument. Ki67 positive cells and regulatory-T-cells (Tregs)
were analyzed after intracellular immune-staining according to
the manufacturer’s protocol (eBioscience). Cytofluorimetric
analysis was carried out by using the FlowJo!software.
Statistical analysis
The statistical analysis was carried out by the GraphPadInstat
3.2 statistical software. The results were expressed as the mean
¡/¡ standard deviation (SD) of four determinations made in
three different experiments, and analyzed by the two-tail Stu-
dent’s t-test. A p value of 0.05 or less was considered statistically
significant. Kaplan Meier descriptive statistics was performed
by the use of SPSS statistical package.
Results
Demographics, chemo-immunotherapy, peptide
vaccination and dose- escalation
Twenty-nine pts with mCRC, 14 males and 15 females, with a
good performance status (ECOG 0–1), who had received at
least two treatment lines (standard poly-chemotherapy ¡/¡
cetuximab and/or bevacizumab) signed an informed consent
and were enrolled between May 2011 and July 2013 (Table 1).
According to the pre-established platform (see pts and meth-
ods), all of them received GOLFIG poly-chemo-immunother-
apy. Seventeen pts, received sc. TSPP vaccination at escalating
dosage [three pts entered the DL-1; 3, the DL-2; 11, the DL-3
cohort] on biweekly bases, starting one week after each chemo-
therapy cycle (concomitant treatment). Twelve pts received
GOLFIG chemo-immunotherapy alone (DL0) for 12 courses
and then maintenance therapy including TSPP vaccination
every three weeks. Two of them were excluded from the study,
due to early disease progression and decline in performance
status. Maintenance therapy included TSPP vaccination
[(300 mg on the day 1 every three weeks) sc.GM-CSF (50 mg at
day, days 1–5 every three weeks), sc.rIL2 (0,5 MIU twice a day,
days 6–15 every three weeks).
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Antitumor activity—Within the 17 pts, who received the
concomitant TSPP/GOLFIG treatment (DL1–3), we recorded
progression of disease (PD) in 9 (52.9%), a partial response
(PR) in 3 (17.64%), and stable disease (SD) in 5 (29.4%) sub-
jects, including four pts (CLCDL2; SACDL2; BGCDL3;
MUCDL3) (23.5%) surviving over 12 mo. On the other hand,
in the 12 pts who were enrolled in the sequential treatment
group, we recorded two PDs occurring before the planned
TSPP vaccination, four PRs (25%), and six SDs (50%). Seven
(63.6%) of these pts (SRCDL0, BLDL0, MLDL0, PGDL0,
MACDL0, PACDL0, DLCDL0) survived more than 12 mo.
(Table 1)
Although this trial was not designed on a comparative set-
ting in term of antitumor activity, we performed an exploratory
descriptive Kaplan Meyer and a Log-Rank test to compare PFS
and OS in pts who received concomitant or sequential treat-
ments, finding a better performance in term of OS in the latter
group (Fig. 1A–B). In our series, the Univariate analysis did
not find any significant correlation of k-ras mutational status
and HLA-A2C haplotype with either PFS (wt-k-ras vs. k-ras
mut status, p: 0.063; HLA-A2C vs. HLA.A2¡ haplotype, p:
0.682) or OS (wt-k-ras vs. k-ras mut status p: 0.203; HLA-A2C
vs. HLA.A2¡ haplotype, p: 0.601) of these pts (data not shown
in figure).
Toxicity profile
The treatment was safe also in this setting of advanced and
largely pre-treated pts. There were no lethal adverse events and
there was no statistical correlation between frequency of
adverse events and TSPP dosage or absence of concomitant
TSPP vaccination (DL0). Similarly, there was no significant
difference when the two groups of pts, receiving concomitant
(DL1–3) or sequential TSPP/GOLFIG treatment (DL0) were
compared. The majority of adverse events were strictly related
to the poly-chemotherapy and consisted in moderate (Grade I–
II) hematologic (anemia and thrombocytopenia) and gastro-
enteric (mucositis) toxicity. A reaction to oxaliplatin was
observed in four pts, who continued the treatment without this
drug. There was no TSPP dose-dependent difference in adverse
event frequency (Table 2). However, it should be underlined
that pts who received a concomitant TSPP/GOLFIG treatment
showed higher frequency of grade 1–2 asthenia, fever, poly-
arthralgia, and biochemical signs of hypothyroidism (six cases)
(rise in TSH levels).(Table 2)
Twelve out of 17 pts who received concomitant treatment
and eight pts who received TSPP maintenance showed a local
reaction at the vaccine injection site, which reflected the occur-
rence of delayed hypersensitivity with appearance of erythema-
tous reactions with swelling and induration still present 72–
96 h later. TSPP vaccination, therefore, resulting safe and well
tolerated did not increase the frequency of grade 3–4 adverse
events associated with GOLFIG regimen. Finally, the frequency
of adverse events per dose level did not allow to identify an
MTD for TSPP (DL0–3) in combination with GOLFIG poly-
chemo-immunotherapy.(Table 2)
Immunobiological monitoring
Hemocytometric analysis—GOLFIG poly-chemotherapy
induced a slight but progressive decline in neutrophil counts,
which was not affected by TSPP vaccination (Table 3). We also
detected a progressive rise in lymphocyte, monocyte, and eosin-
ophil counts which, again, was not influenced by concomitant
Table 1. Patients’ characteristics. Mut: mutated; Wt: wild type; MAINT: number of vaccine maintenance therapy cycle; PD: disease progression; SD: stable disease; PR: par-
tial response.
CODE Sex ECOG Metastatic sites Previous treatment lines K-ras HLA-A2 GOLFIG courses MAINT Type of response Overall Survival months
LM/C/DL1 F 2 Peritoneum, lung, liver 2 Mut A24 6 2 PD 5
CV/C/DL1 M 1 Peritoneum, lung, liver 6 Mut A3.24 5 0 PD 4
BF/C/DL1 M 2 Peritoneum, lung, liver 3 Mut A11.6 3 0 PD 2
CL/C/DL2 F 0 Peritoneum, nodes 3 Mut A2 12 1 PD 19
FA/C/DL2 F 2 Colon, lung, liver 6 Wt A11.6 11 0 SD 6
SA/C/DL2 M 0 Lung, liver, nodes 5 Wt A2 10 6 PR 11
SS/C/DL3 F 0 Brain, lung, liver, nodes 5 Mut A23.2 12 3 PR 8
BA/C/DL3 F 1 Colon, lung, liver, nodes 2 Mut A2 11 0 SD 7
SA/C/DL3 F 2 Peritoneum, lung, liver 5 Mut A2 12 0 PD 6
DA/C/DL3 F 2 Peritoneum, lung, liver 4 Mut A1.11 10 0 PD 6
MP/C/DL3 M 1 Peritoneum, lung, liver 6 Mut A2 6 0 SD 14
PM/C/DL3 M 1 Peritoneum, lung, liver 2 Mut A11.2 11 3 SD 9
MU/C/DL3 F 1 Soft tissue, nodes 2 Wt A24.2 12 32 SD 42C
PA/C/DL3 M 1 Peritoneum, lung, liver 7 Wt A2 11 3 PR 8
CA/C/DL3 M 2 Peritoneum, lung, liver 3 Mut NA 6 0 PD 13
BG/C/DL3 F 0 Peritoneum, lung, liver 3 Wt A2 10 8 SD 2
NR/C/DL3 F 2 Peritoneum, lung, liver 2 mut A2 3 0 PD 2
SR/C/DL0 M 0 Lung, liver 3 wt A23.2 12 5 SD 12
DG/C/DL0 F 0 Lung, liver 3 wt A33 10 5 PR 10
BL/C/DL0 F 0 Lung, liver 2 wt A3.29 10 9 SD 15
ML/C/DL0 F 0 Peritoneum, lung, liver 2 mut A2 10 9 SD 8
VP/C/DL0 M 1 , lung, liver 2 wt A2 7 1 SD 16
PG/C/DL0 M 1 lung, liver 2 Wt A24.3 9 12 SD 32C
SA/C/DL0 M 2 Peritoneum, lung, liver 3 wt A1.3 7 0 PD 5
MA/C/DL0 M 0 lung, liver 2 mut A1 9 32 PR 33C
PA/C/DL0 M 0 lung, liver 2 wt A3.24 11 14 PR 17
DL/C/DL0 F 0 Peritoneum, lung, liver 3 wt A2 9 4 SD 13
VC/C/DL0 M 0 Peritoneum, lung, liver 2 mut A23,2 10 7 PR 7
PA/C/DL0 F 1 Peritoneum, lung, liver 3 wt 23.26 9 4 SD 16
e1101205-4 P. CORREALE ET AL.
TSPP vaccination. When the hemocytometric monitoring
curves of pts in DL1–3 and DL0 groups were compared, we
were unable to demonstrate any statistical difference in lym-
phocyte (p D 0.605), monocyte (p D 0.807) and eosinophil (p
D 0.199) count monitoring.(Fig. 1C–E)
Serologic analysis of systemic inflammatory markers—An
analysis of serological inflammatory markers revealed a trend
to progressive decline in CRP and an increase in ESR in both
group. Pts who received the sequential treatment (DL0), how-
ever, showed lower levels of inflammatory markers CRP (p D
0.041) and ESR (p < 0.001) at baseline and along the treat-
ment.(Table 3)
Serologic analysis of auto-antibodies
The serum monitoring of AAbs potentially indicative of
autoimmunity, showed a progressive and significant increase
in ENA, p-ANCA, and c-ANCA only in the group of pts
who received the concomitant treatment (DL1–3) and no
change in the other group (DL0). Differences in ANA,
ENA, c-ANCA, and p-ANCA values between the concomi-
tant and sequential treatment groups resulted statistically
significant (p values for ANA and ENA, c-ANCA, p-ANCA
value curves were 0.049, 0.0345, 0.0163, and 0.0412, respec-
tively) (Table 3 and Fig. 1F–H). Our analysis did not reveal
particular changes in other AAbs such as ASMA, ANCA,
and anti-thyroid Abs.
Flow cytometry
Flow cytometry analysis performed on the peripheral blood
of the pts receiving the concomitant and sequential treat-
ment modules did not show differences and changes in the
percentages of peripheral CD3CCD4C (DL1–3 vs. DL0
group; p = 0.22) and CD3CCD8C CTLs (DL1–3 vs. DL0
group; p D 0.145). A further analysis of these T cells, simi-
larly, did not show differences in the percentages of
CD3CCD4CCD45¡memory T cells (DL1–3 vs. DL0 group; p
Figure 1. The upper figures (first three rows) represent the fold change modulation relative to baseline values of plotted percentages of peripheral Treg, Tcm, Tem of the pts
enrolled in the trial and who received the concomitant (DL 1 -3) (left panels) and sequential (DL-0) treatment modules (right panels). Statistical significance was calculated
by performing the one-way Anova analysis of variance, post-test Bonferroni with 95% IC. The bottom figures (last four rows) represent the fold change modulation rela-
tive to baseline values of serum level of IFNg, IL-17, IL-4, and IL10 of the pts who received the concomitant (DL1 -3) (left panels) or the sequential treatment modules
(DL0) (right panels). Statistical significance was calculated by performing the one-way Anova analysis of variance, post-test Bonferroni with 95% IC. Post-3, i6, i12, i15,and
i18 represent the number of treatment courses received by the pts. Pts in the DL1 -3 group received concomitant TSPP vaccination and GOLFIG chemo-immunotherapy
and then TSPP maintenance starting after 12 courses (Post-12). Pts in the DL0 group received GOLFIG chemo-immunotherapy alone and then TSPP maintenance starting
after 12 courses (Post-12).
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D 0.301). Both group of pts receiving the concomitant and
sequential treatment module showed an early increase in
peripheral CD4CCD25CFoxP3C Tregs which was lost on the
long-term (Fig. 2). There was no difference between the
two groups of pts (DL1–3 vs. DL0, p= 0.21) suggesting that
this effect was related to the presence of GM-CSF and IL-2
in the GOLFIG regimen and not to TSPP administration.
The group of pts receiving the concomitant treatment mod-
ule instead, showed an increase in central memory
(CD8CCD45RA¡CCR7C) T cells (Tcm), while that receiving
the sequential module showed an progressive increase in
effector memory T cells (Tem) (CD8
CCD45RA¡CCR7¡).
(Figs. 2 and 3)
Finally, it was also recorded a trend to increase in peripheral
natural killer (NK) cells (CD3¡CD56CCD16C) in both groups
of pts, which achieved statistical significance only in the DL0
group. Differences between the two pts’ groups were not signifi-
cant (DL1–3 vs. DL0, p D 0.49) (Table 3). The increase in this
cell subpopulation seems to be related to the presence of
immune-adjuvant cytokines in the GOLFIG regimen and not
to the TSPP vaccination.
Cytokine analysis
A cytokine analysis performed on the serum of these pts
showed a completely different profile between the two groups
of pts receiving concomitant and sequential treatment module.
Our analysis showed no changes in TNFa, IL12 levels (data not
shown), IL6 and IL8 (Table 3) while, a significant and progres-
sive increase in IFNg and IL-4 was observed in the pts who
received the concomitant treatment (DL1–3) (Fig. 2). In the
same group, there was also a trend increase in IL10, which did
not achieve statistical significance probably, for the small sam-
ple of pts. We finally, observed a significant increase in IL17
levels during the maintenance treatment in both group of pts
which seems strictly related to the TSPP vaccination (Fig. 2).
Table 2. Adverse events. DL: TSPP dose level.
Frequency of adverse events
DL0 (11 pts) DL1 (3 pts) DL2 (3 pts) DL3 (12 Pts)
Adverse events G 1 G2 G 3 G 4 G 1 G2 G 3 G 4 G 1 G2 G 3 G 4 G 1 G2 G 3 G 4
Leukocytopenia 2 4 2 3 5 1
Anemia 4 8 1 2 2 5 2
Thrombocytopenia 2 1 2 1 2 2 1 1
Nausea / Vomit 1 3 1 1 2
Preaffable pain 1 2 2
Addominal pain 2 1 3
Diarrhea 2 1 1 0 0
Conjunctivitis 1 2 1 1 4
Cutaneous reaction 1 1 1
Cough 1 1 1 0 0
Hiccup 1 1
Nettle rash 1 1
Dyspnea 1 1
Poliarticular syndrome 3 2 1 3
Infection/ sepsi 2 1 2 2 1
Fever 1 1 2 2 3 2 1
Asthenia 1 1 2 3 2 1
Sensorial Neurotoxicity 3 1
Transaminase rise 4 1 2 1
Hypothyroidism 2 3
Hypotension 1 1
Hypertension 1 1 1 1 3
Nether arts edema 3 3 1 2 1 2 2 1
Table 3. Treatment groups.
DL1–3 (17 pts) DL0 (12 pts)
Baseline Post 3 Post 6 Post 12 Baseline Post 3 Post 6 Post 12 p
Neutrophilsmigl/mm3 4.7¡/¡0.7 4.1¡/¡0.75 3.5¡/¡0.2 2.8¡/¡0.2 4.4¡/¡0.4 4.3¡/¡0.3 3.0C/0.65 4.6¡/¡0.7 0,6
CPRmg/mL 3.5¡/¡0.9 3.9 ¡/¡1.2 2.3C/0.47 4.5¡/¡1.1 2.16C/0.9 1.6 ¡/¡0.6 1.4 ¡/¡0.6 1.0¡/¡0.2 0.041
ESRmm/h 69.9C/8.3 75.3C/10.4 79.1C/7.5 85.4¡/¡11.2 40.7C/7.8 52.8¡/¡8.2 56.1C/9.9 58.1C/11.6 0.00018
ANApositive patients 2/17 2/17 6/17 5/17 0/12 0/12 0/12 1/12 <0.05
NK% of plotted cells 5.41¡/¡5 8.3¡/¡1.2 9.6¡/¡7.6 8.6¡/¡1.9 5.7¡/¡3.5 10.7¡/¡1 11¡/¡4.4 7.9¡/¡1.4 0.49
IL6pg/mL 4.8¡/¡2 6.4¡/¡2 5.5¡/¡1 4.4¡/¡2 1.1¡/¡0.6 5.2¡/¡2.4 3.1¡/¡1.3 3.5¡/¡0.2 0.09
IL8pg/mL 36.8¡/¡8 54¡/¡18 17¡/¡2 13.3¡/¡4.4 56.6C/12.3 62.7¡/¡11.3 16¡/¡1.1 37.6C/12.2 0.82
Neutrophils – DL-1–3, baseline vs. 6th vs. 12th course, p <0 .01; DL-0, baseline vs. 6th course, p D 0.05.
CPR- DL-1–3 values, baseline vs. 6th, p D 0,049; DL0 values, baseline vs. 6th vs. 12th course, p < 0 .05.
NK- DL0 values, baseline vs. 6th course, p D 0.04.
e1101205-6 P. CORREALE ET AL.
The ability of TSPP vaccination to increase the precursors fre-
quency of TSPP specific CTL precursors was demonstrated by
IFNg ELISPOT assay in the previous study and was not corre-
lated with either dosage of combined treatment [22 and data
not shown].
Discussion
Our results confirm the safety and immune-modulating activi-
ties of TSPP in concomitant and sequential combination with
GOLFIG chemo-immunotherapy. The MTD of this peptide
could not be identified, while its MEBD was recognized at the
dosage of 300 mg which was associated with the highest fre-
quency of biomodulatory effects and longer survival. TSPP vac-
cination was associated to a high frequency of local immune-
reactions at the vaccine injection site, rhinitis, conjunctivitis,
and poly-arthralgia as shown in the previous study.22 TSPP
vaccination did not increase the frequency and severity of the
adverse events associated with the GOLFIG chemo-immuno-
therapy, which occurred with the same frequency in the groups
of pts who received either the concomitant or the sequential
treatment modules. On the whole, the frequency of adverse
Figure 2. Kaplan Meyer descriptive for statistics Panels (A)–(B) represent median PFS (A) and OS (B) in pts enrolled in the concomitant (DL1–3) and sequential (DL0) treat-
ment modules. Median PFS, DL1–3 vs. DL0: 3 i/i 0.738 (95% IC: 2.55–5.44) mo vs. Seven _i/_i 0.818 (95% IC:4.64–7.85), p= 0.340; median OS, DL1–3 vs. DL0: 8 i/i 0.038 (95%
IC: 6.13–12.69) mo vs. 16 i/i 1.67 (95% IC: 10.17–17.05) mo; p D 0.049 by log rank test. Panels (C)–(E) represent peripheral blood cell counts in mCRC pts enrolled in the
TSPP/VAC1 arm-C trial, at baseline and before each treatment course. Lymphocyte counts (C), monocyte counts (D), eosinophil counts (E). Results are expressed as a num-
ber of cells £ 102/sqmm i/standard error. Panels (F)–(H) represent serum auto-antibodies in mCRC pts enrolled in the TSPP/VAC1 arm-C trial, at baseline and before each
treatment course. ENA (F), c-ANCA (G), and p-ANCA (H). Results are expressed as a units/mLi/istandard error. Symbols represent the groups of pts who received TSPP vac-
cination as concomitant (&) or sequential treatment modules (^^^). Pts in the DL1–3 group received concomitant TSPP vaccination and GOLFIG chemo-immunotherapy
and then TSPP maintenance starting after 12 courses (Post-12). Pts in the DL0 group received GOLFIG chemo-immunotherapy alone and then TSPP maintenance starting
after 12 courses (Post-12). Statistical significance (p <0 .05) with the co-respective baseline value is represented by an asterisk.
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events was similar to that reported in previous clinical trials
investigating the GOLFIG regimen alone in pretreated mCRC
pts.15,19,20 The results of the present study suggest that the
TSPP vaccine in combination with GOLFIG poly-chemother-
apy is a feasible treatment for pretreated mCRC pts. The
sequential treatment appeared to be more active than the con-
comitant in terms of OS (p D 0.049), and in both cases, it was
not affected by k-ras mutational status and HLA-A2 haplotype
. These results appear intriguing, although with significant limi-
tation related to the small number of enrolled pts. We have pre-
viously demonstrated that the GOLFIG regimen is a very active
treatment, that enhances TS specific CTL precursors and pro-
motes an effective anticancer CTL response correlated with the
occurrence of autoimmunity and longer survival in mCRC
pts.20,21 These features lead us to believe that the GOLFIG regi-
men, which combines poly-chemotherapy and immune-adju-
vant cytokines, when supported by TSPP vaccination, in
addition to a significant reduction of tumor burden, could also
promote a mechanism of antigen cascade and cross-presenta-
tion triggering an efficient specific immune-response with
poly-antigen specificity.
In the present study, TSPP vaccination given concomitantly
with GOLFIG treatment was associated with systemic and clini-
cal signs of immune-activation. This assumption was supported
by the finding of a coordinate and progressive rise in lympho-
cytes, monocytes, and appearance of AAbs such as ANA, ENA
pANCA e cANCA which are associated with the most common
autoimmune-diseases. Consistent with the last finding, we also
detected clinical signs of autoimmunity like poly-artharalgia,
hypothyroidism, rhinitis, conjunctivitis, and fever in some pts.
Some of these events were sporadically observed also in pts
who received GOLFIG chemo-immunotherapy alone, as shown
in previous studies,20,21,26 and similarly, in the pts enrolled in
the DL0 group of the present trial, prior receiving TSPP vacci-
nation. By comparing the concomitant with sequential treat-
ment groups, we also recorded a significant difference in term
Figure 3. Flow cytometry analysis: Central memory T cells (TCM;CD45RA
¡CCR7C) and effector memory T cells (TEM; CD45RA¡CCR7¡) gated on CD3CCD8C lymphocytes (A)
of representative patient PBMCs (DL3), isolated at the baseline (C) and after six treatment lines (D) Regulatory T cells (Treg; CD25
CFoxp3C) gated on CD3CCD4C lympho-
cytes (B) of representative patient PBMCs, isolated at the baseline (E) and after six treatment lines (F).
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of systemic inflammatory status with much higher serum level
of CRP e ESR in the first group. This finding could be indicative
of chronic inflammation which, in turn, may affect the immu-
nological activity of TSPP vaccination as described in litera-
ture.27-31 The reasons explaining the difference in
inflammatory status in the two groups of pts are not clear. It
could be either related to an effect of the combined treatment
or just to a specific feature of the pts enrolled in the study and
deserves to be further investigated with a more homogenous
patient population. In line with previous results performed on
mCRC pts who had received the GOLFIG regimen, we also
detected an increase in Tregs in both patient groups which is
lost on the long term. The treatment associated-rise in Tregs, as
reported by other authors,32 can be considered as an inhibitory
feedback response to an efficient antigen specific immune-reac-
tion in order to avoid dangerous over-reactions and auto-
immunity, which mainly occur in a chronic inflammatory sta-
tus under selective cytokine pressure, or dependent by the IL-2
administration.27-32 In both groups of pts, Treg rise was how-
ever, lost after the first 10–12 treatment courses, as probably
caused by GOLFIG regimen.15,20 This finding, together with
lower systemic inflammatory status, could contribute to explain
the more significant antitumor activity of TSPP vaccine in the
sequential treatment group (DL0). In fact, these pts received
vaccination when the Tregpopulation is exhausted and there-
fore, unable to affect the immunological activity of TSPP.27,28,32
The results of the immunological analysis, which showed a gen-
eral treatment-associated increase in peripheral lymphocyte
counts, provides a further support to this hypothesis. In this
context, there was no difference in the percentages of
CD3CCD4C or CD3CCD8C T cells, however, in the DL0 group
we found an increase of the Tem subset during TSPP vaccina-
tion (started after 12 GOLFIG courses), which was not detected
in the concomitant treatment group. This is a very efficient
CTL subset which derives by Tcmmaturation in the presence of
immune-specific micro-environmental conditions (cytokines,
chemokines, adhesion molecules, etc.).33-37 This hypothesis is
supported in our pts, by the data concerning the treatment-
related increase of IL-17, a cytokine which is able to sustain a
local immune-reaction in the tumor site. In our pts, we also
detected a treatment-related increase of IL-4 and trend increase
of IL-10, which could be related to Treg stimulation and/or of
an intrinsic ability of TSPP vaccine to promote a Th2 humoral
response as confirmed by a systemic progressive increase of
AAbs in these pts. Additionally, we also found a significant
increase in IFNg, a Th1 cytokine, which is strongly involved in
the antigen specific CTL response in the DL1–3 group pts. A
last consideration concerns the expansion of peripheral NKs in
both groups of pts during the first 10 treatment courses. This
finding, which seems to be sustained by GM-CSF and IL-2
cytokines, both present in the GOLFIG regimen, suggests that
this treatment is a valid support to TSPP vaccination. NK cells
in fact, together with an innate ability to kill metastatic cancer
cells, are also able to produce IFNg and enhance the antigen
presenting ability of peripheral DCs.38 We can conclude that
TSPP-vaccination in combination with the GOLFIG chemo-
immunotherapy is safe and immune-biologically active in pre-
treated mCRC pts. We have also provided preliminary evidence
of a promising antitumor effect in both groups of pts receiving
either the concomitant or the sequential treatment. The latter
group of pts in particular, showed an unexpected PFS and OS
median of 7 and 16 mo, respectively, which resulted signifi-
cantly much longer than that reported in other clinical trials
investigating newest drugs in pre-treated mCRC pts, which
rarely show a median PFS and OS longer of 2 and 6 mo, respec-
tively. We believe that our results provide the rationale to
design further trials in mCRC pts aimed to investigate the anti-
tumor activity of TSPP vaccine in pts who have received a
frontline chemo-immunotherapy line.
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